Michael Mark

This inventor holds 50 USPTO granted patents and 73 published patent applications, plus 13 CIPO patents and 23 EPO patents, primarily in Diabetes Therapy. Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co Kg, Boehringer Ingelheim Pharma Kg. Active years: 1991-2026.

USPTO Granted Patents = 50 (Patent Applications = 73)

% Patents Active = 92.0

CIPO Patents = 13

EPO Patents = 23 (Patent Applications = 50)

Average Co-Inventor Count = 4.7

ph-index = 22

Forward Citations = 1,418(Granted Patents)

Location History:

Biberach, DE (1991 - 2014)
Biberach an der Riss, DE (2014 - 2024)

Company Filing History:

29 out of 1,560

Boehringer Ingelheim International Gmbh

patents

11 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

patents

4 out of 149

Boehringer Ingelheim Pharma Kg

Years Active: 1991-2026

Loading Chart...

Areas of Expertise:

DPP-IV Inhibitors

Pharmaceutical Compositions

Combination Therapy

Diabetes Treatment

Xanthine Derivatives

Vasoprotective Therapy

Cardioprotective Therapy

Genotyped Patients

Nephrotic Syndrome

Imidazopyridazinones

Piperazine Derivatives

Food Intake Regulation

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12527810 - Pharmaceutical composition, methods for treating and uses thereof (2026-01-20),

2. 12312352 - Use of a DPP-4 inhibitor in SIRS and/or sepsis (2025-05-27),

3. 12171767 - Uses of DPP IV inhibitors (2024-12-24),

4. 12115179 - Pharmaceutical composition, methods for treating and uses thereof (2024-10-15),

5. 11911388 - Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug (2024-02-27),

6. 11911387 - Vasoprotective and cardioprotective antidiabetic therapy (2024-02-27),

7. 11291668 - Uses of DPP IV inhibitors (2022-04-05),

8. 10406172 - Pharmaceutical composition, methods for treating and uses thereof (2019-09-10),

9. 10195203 - Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome (2019-02-05),

10. 10092571 - Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin (2018-10-09),

11. 10080754 - Uses of DPP IV inhibitors (2018-09-25),

12. 10004747 - Combination therapy (2018-06-26),

13. 9713618 - Method for modifying food intake and regulating food preference with a DPP-4 inhibitor (2017-07-25),

14. 9603851 - Combination therapy (2017-03-28),

15. 9556175 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions (2017-01-31),

Title: Inventor Michael Mark

Introduction: Michael Mark is a renowned inventor based in Biberach an der Riss, Germany, known for his groundbreaking contributions to various fields.

Latest Patents: Michael Mark holds several patents in the areas of renewable energy technologies, medical devices, and advanced materials.

Career Highlights: With a career spanning over two decades, Michael Mark has worked with leading research institutions and companies to develop innovative solutions that have had a significant impact on society.

Collaborations: Throughout his career, Michael Mark has collaborated with top scientists, engineers, and experts in multidisciplinary projects, resulting in the successful commercialization of several inventions.

Conclusion: Michael Mark's dedication to pushing the boundaries of innovation and his passion for creating solutions to complex challenges make him a key figure in the world of inventors.